New shot aims to reverse cervical precancer without surgery
NCT ID NCT07668960
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an injection called BBM-C101 in 60 women with high-grade cervical precancer linked to HPV16 or HPV18. The goal is to see if the drug is safe and can shrink or eliminate abnormal cells, potentially offering a non-surgical alternative. Participants receive four weekly shots at different doses, and doctors monitor side effects and lesion regression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BBM-C101 injection
- What this could lead to
- If successful, this could offer a non-surgical treatment option for cervical precancerous lesions caused by HPV16/18, potentially reducing the need for invasive procedures.
- What could go wrong
- This is an early-phase trial with only 60 participants, so results may not apply broadly. The treatment may cause side effects or fail to clear the lesions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX ASSOCIATED WITH HUMAN PAPILLOMAVIRUS (HPV) TYPE 16 AND/OR HPV TYPE 18 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Provincial People's Hospital
Zhangzhou, Henan, 450003, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
-
Qilu Hospital of Shandong University
Jinan, Shandong, 250012, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400010, China